Becoming a Biotech CEO: Jodie Morrison on The Long Run

Today’s guest on The Long Run is Jodie Morrison.

Jodie is the acting CEO at Waltham, Mass.-based Q32 Bio. It’s a company developing treatments for autoimmune and inflammatory diseases. It has an antibody in development with Horizon Therapeutics aimed at IL-7 receptor alpha, in Phase II for the treatment of atopic dermatitis. It also has wholly-owned programs aimed at the complement system of the innate immune system, with the intent of making treatments that are tissue-targeted.

Jodie Morrison, acting CEO, Q32 Bio

She came to this position after a series of executive roles and board positions. Her first stint as a CEO, at Tokai Pharmaceuticals, didn’t end well. She dusted herself off and came back to play a role in back-to-back successful outcomes at Syntimmune, Keryx, and Cadent Therapeutics.

In this episode, we talk about how Jodie developed the confidence to lead from some of her early career experiences, how she thinks about hiring, and, at the end of the conversation, she provides some advice to young women seeking to grow and advance in the biotech industry.

And now for a word from the sponsor of The Long Run.

Occam Global is an international professional services firm focusing on executive recruitment, organizational development and board construction. The firm’s clientele emphasize intensely purposeful and broadly accomplished entrepreneurs and visionary investors in the Life Sciences. Occam Global augments such extraordinary and committed individuals in building high performing executive teams and assembling appropriate governance structures. Occam serves such opportune sectors as gene/cell therapy, neuroscience, gene editing, the intersection of AI and Machine Learning and drug discovery and development. 

Connect with Occam:

www.occam-global.com/longrun

Now, please join me and Jodie Morrison on The Long Run.